Search
for
Sort by
Research 181–210 of 1000+
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- Alopecia Totalis/Universalis
- Immune therapies for alopecia areata: evidence and new perspectives
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Autophagy: Guardian of Skin Barrier
- Botulinum Toxins in Medical and Cosmetic Dermatology
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Tinea capitis caused by Trichophyton violaceum in an immunocompetent elderly patient: a case report and review of literature
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Peer Review Report For: Pattern changes of cutaneous dermatoses among Iraqi women preceding and during the COVID-19 pandemic [version 3; peer review: 2 approved]
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Ritlecitinib: First Approval
- New drugs under investigation for the treatment of alopecias
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Skin Disorders
- Acquired scalp alopecia. Part II: A review
- Dermatologic therapy: December 1986 to December 1987
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Nonscarring alopecia after temporal lifting technique with dermal fillers
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Scarring Alopecia in a 66‐Year‐Old Woman
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Eyebrow and Eyelash Alopecia: A Clinical Review
- Trends in dermatological presentations at the emergency department of a tertiary hospital in Singapore: a 4-year analysis pre- and during COVID-19